Vinay Prasad Returns as FDA's CBER Head After Abrupt Exit

Vinay Prasad is rejoining the FDA as head of the Center for Biologics Evaluation and Research (CBER) following a recent, abrupt departure marked by political controversy. His reinstatement was made at the FDA's request and includes oversight of vaccine and gene therapy regulation. This leadership turnaround underscores ongoing tensions in vaccine and gene therapy policy at the agency.